Cannabis Strategic Ventures
Cannabis Strategic Ventures engages in the cultivation of marijuana products in the United States. It incubates, develops, and partners within the cannabis and ancillary sectors. The company is based in Los Angeles, California.
Cannabis Strategic Ventures (NUGS) - Net Assets
Latest net assets as of June 2022: $-8.68 Million USD
Based on the latest financial reports, Cannabis Strategic Ventures (NUGS) has net assets worth $-8.68 Million USD as of June 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.85 Million) and total liabilities ($19.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.68 Million |
| % of Total Assets | -80.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | -182.81% |
| 10-Year Change | N/A |
| Growth Volatility | 685.28 |
Cannabis Strategic Ventures - Net Assets Trend (2014–2022)
This chart illustrates how Cannabis Strategic Ventures's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cannabis Strategic Ventures (2014–2022)
The table below shows the annual net assets of Cannabis Strategic Ventures from 2014 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-03-31 | $-8.86 Million | -11.73% |
| 2021-03-31 | $-7.93 Million | -37.29% |
| 2020-03-31 | $-5.78 Million | -1466.62% |
| 2019-03-31 | $422.65K | -96.05% |
| 2018-03-31 | $10.70 Million | +26188.49% |
| 2017-03-31 | $-41.01K | +69.07% |
| 2016-03-31 | $-132.61K | -136.85% |
| 2015-03-31 | $-55.99K | +68.55% |
| 2014-03-31 | $-178.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cannabis Strategic Ventures's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5496452700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $366.82K | % |
| Other Comprehensive Income | $1.15 Million | % |
| Other Components | $49.43 Million | % |
| Total Equity | $-8.86 Million | 100.00% |
Cannabis Strategic Ventures Competitors by Market Cap
The table below lists competitors of Cannabis Strategic Ventures ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Heartsoft Inc
PINK:HTSF
|
$0.95 |
|
Firemans Contractors
PINK:FRCN
|
$0.95 |
|
Nilam Resources Inc
PINK:NILA
|
$0.95 |
|
Premium Exploration Inc
PINK:PMMEF
|
$0.95 |
|
eFotoXpress Inc
PINK:EFOT
|
$0.95 |
|
Western Pacific Minerals Ltd
PINK:WPMLF
|
$0.95 |
|
Triumph Apparel Corporation
PINK:TRUA
|
$0.95 |
|
New Oriental Energy
PINK:NOEC
|
$0.95 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cannabis Strategic Ventures's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -7,929,668 to -8,860,141, a change of -930,473.
- Net loss of 8,597,000 reduced equity.
- Other comprehensive income decreased equity by 868,399.
- Other factors increased equity by 8,534,926.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.60 Million | -97.03% |
| Other Comprehensive Income | $-868.40K | -9.8% |
| Other Changes | $8.53 Million | +96.33% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cannabis Strategic Ventures's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-03-31 | $-0.01 | $0.00 | x |
| 2016-03-31 | $-0.01 | $0.00 | x |
| 2017-03-31 | $0.00 | $0.00 | x |
| 2018-03-31 | $0.06 | $0.00 | x |
| 2019-03-31 | $0.00 | $0.00 | x |
| 2020-03-31 | $-0.02 | $0.00 | x |
| 2021-03-31 | $-0.03 | $0.00 | x |
| 2022-03-31 | $-0.03 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cannabis Strategic Ventures utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -87.25%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-572.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 13.22% | 17.72x | 0.00x | $67.01K |
| 2015 | 0.00% | 7.90% | 52.98x | 0.00x | $17.41K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-60.52K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $90.07K |
| 2018 | -78.60% | -2439.77% | 0.03x | 1.16x | $-9.48 Million |
| 2019 | -5071.05% | -3053.22% | 0.25x | 6.71x | $-21.47 Million |
| 2020 | 0.00% | -382.55% | 0.13x | 0.00x | $-8.48 Million |
| 2021 | 0.00% | -38.64% | 0.91x | 0.00x | $-4.85 Million |
| 2022 | 0.00% | -87.25% | 0.88x | 0.00x | $-7.71 Million |
Industry Comparison
This section compares Cannabis Strategic Ventures's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cannabis Strategic Ventures (NUGS) | $-8.68 Million | 0.00% | N/A | $0.95 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |